Home / Resource Library / Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial
Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial